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Summary and Key Points 
1. The practice of radiation oncology is based on five disciplines: clinical 
oncology, radiobiology, medical physics, oncologic imaging, and 
computer science. 
2. Radiation therapy is a regional treatment that can be utilized as the 
sole treatment of a cancer or can be combined with surgery and/or 
chemotherapy in a multimodality regimen. 
3. Definitive treatment (therapy with curative intent) can eradicate a 
tumor while sparing the organ that harbors it. 
4. Severe acute effects may be acceptable if the treatment goal is cure. 
Supportive care and management of acute effects is critical in effective 
treatment delivery. 
5. The impact of a given radiation dose is dependent upon the fraction 
size, treatment duration and treated volume. 
6. Prescription radiation doses for cure are determined largely by normal 
tissue tolerances, the risk and acceptability of late effects. 
7. The intent of palliative treatment is to relieve symptoms (rather than 
eliminating tumor). It is typically delivered in a relatively short 
treatment course, with fewer side effects. 
A Brief History of Radiotherapy 
Introduction 
Radiation oncology uses ionizing radiation to treat cancer (and 
occasionally a few benign conditions). Radiotherapy or radiation therapy 
(RT) was initially developed in conjunction with diagnostic radiology, but 
has evolved into a separate specialty. Currently, more than 50% of cancer 
patients undergo RT at some point during the course of their cancer. Most 
receive treatment with curative intent (definitive therapy). Patients with 
incurable disease receive shorter courses of therapy to relieve cancer-
induced symptoms designed to minimize acute side effects. 
The acute side effects of RT are often milder than either chemotherapy or 
radical surgery; most patients find it the easiest portion of their therapy. 
While ionizing radiation damages both normal and cancerous cells, normal 
cells have greater capacity to repair this damage and carefully 
administered treatment can eradicate cancer cells while relatively sparing 
the organ that harbors them. For example, a laryngeal tumor and its 
draining nodes can be cured while sparing the voice and neck muscles. 
Although RT can be used alone, it is often combined with surgery and/or 
chemotherapy in a multimodality regimen that benefits from the unique 
advantages of each modality. Combined modality therapy does run the 
risk of increased toxicity because of each treatment’s side effects, so these 
regimens should be carefully designed and tested in clinical studies. 
RT consists of two modalities: teletherapy and brachytherapy. Teletherapy 
utilizes x-ray or sub-atomic particle beams, delivered by a machine 
positioned a distance (typically, a meter) from the patient. Brachytherapy 
utilizes radiation emanating from radioactive sources implanted inside the 
patient’s body, either temporarily or permanently. Both modalities have 
been in use for over a century. 
In order to deliver safe and effective RT, the radiation oncologist must 
master five foundation disciplines: clinical oncology, radiobiology, 
oncologic imaging, computer science and medical physics. 
Clinical Oncology 
Effective practice of radiation oncology depends on a sound 
understanding of clinical oncology and basic sciences. This knowledge 
must include: 
 Principles of cancer pathology, medical oncology and surgical 
oncology 
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 Gross anatomy and radiographic anatomy 
 Natural history of each cancer 
 General clinical care of the cancer patient including supportive 
care, management of cancer symptoms and treatment effects 
Anatomy, the precise location of tumor in the patient and the natural 
history of a cancer are the basis of treatment planning for each patient. 
For example, careful recording of precise lymph node metastasis locations 
and risk of involvement of those locations in a study population dictate 
shape of fields to cover areas at greatest risk of microscopic tumor 
spread.1 
Radiobiology 
Radiobiology studies the impact of ionizing radiation on biological 
molecules, living cells and tissues. Whether an ionizing ray hits a molecule 
upon striking a cell is a random event. Statistically, a ray is most likely to 
strike the most common molecule in the cell, water. The ionizing ray 
causes water molecules to break apart into ion pairs, producing the highly 
reactive hydroxyl radical. Free radicals bounce around in the cell, and may 
strike other molecules, usually water, causing a cascade that increases 
the number and density of free radicals. Ultimately, one or more of these 
radicals may randomly strike a molecule of DNA, resulting in single or 
double strand DNA breaks. Without functioning DNA, the cancer cells 
cannot reproduce properly or repair themselves, and the cells transition to 
apoptosis. Apoptosis (programmed cell death) is the capacity of a cell to 
destroy itself if its DNA is irrevocably damaged. 
A cell has several endogenous agents that are protective against radiation 
damage. The continued existence of free radicals depends on the 
concentration of the primary cellular defense- glutathione, which destroys 
free radicals. Enzymes that metabolize reactive oxidative species, 
including catalase, superoxide dismutase, and glutathione peroxidase, 
also may protect cells from radiation. Oxygen is a radiosensitizer because 
it extends the existence of free radicals by a factor of 3. Cells in a hypoxic 
environment are relatively radioresistant (by the same factor of 3; this is 
not a coincidence). 
The body can usually repair single strand breaks, and sometimes can 
repair double strand breaks. Lethal damage results in mitotic cell death; 
damage that can be repaired is called 'potentially lethal damage'. Death of 
a cell line after lethal damage may take several mitotic cycles and 
therefore, depending on cell cycle time, as long as several months. A cell 
is most sensitive to radiation when it is undergoing mitosis; conversely, 
cells in G0 and the late S phase are relatively radioresistant. After cell 
death, the body must resorb the cell remains, and scars may form. So 
tumors usually shrink slowly, and sometimes a mass will remain that is 
simply a scar. 
RT traditionally has been fractionated, which means delivered in multiple 
small daily doses, to maximize the effect on tumor cells and minimize the 
late effects on normal tissues. Acute side effects are largely due to the 
effect of radiation on the rapidly dividing normal cells of the body, such as 
skin and mucous membranes. Tumor cells are actively dividing, so tumors 
tend to respond in the same way as normal cells that actively divide. 
Due to very different pathophysiology, occurrence of acute effects do NOT 
predict for occurrence of late effects. Late effects are largely due to 
microvascular damage that resembles that caused by diabetes mellitus, 
loss of parenchymal cell function and scarring. It is important to remember 
that late effects may occur many years after treatment. 
The 4 R’s of radiobiology: reoxygenation, repair, redistribution, and 
repopulation are the reasons radiation oncologists fractionate radiation. 
Reoxygenation 
When a tumor is irradiated, the better-oxygenated cells in the 
periphery of the tumor deposit are more likely to die. As these cells 
die during the course of therapy, O2 penetrates more deeply into the 
tumor, and reach cells that had previously been poorly oxygenated. 
Hence, fractionated radiotherapy results in the induction of 
radiosensitivity in cells that had originally been radioresistant by the 
phenomenon of ‘reoxygenation’. 
Repair 
Potentially lethal damage is damage which may be repaired; both in 
tumor cells and most importantly in normal, healthy, non-cancerous 
tissue within the radiation field. This process is felt to be largely 
complete in about 6 hours. Repair decreases risk of late effects. 
Redistribution 
Redistribution refers to the movement of cells into different phases of 
the cell cycle. Since cells in the late S phase and G0 are relatively 
resistant to radiation, multiple treatments enhance the chance that 
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any given cell will receive treatment during a sensitive phase in the 
cell cycle. Redistribution makes radiation therapy more effective. 
Repopulation 
Hopefully, all tumor cells are encompassed by the treatment and 
much normal tissue is not. In that case, normal cells can migrate from 
un-irradiated tissue into the target volume to replace damaged cells 
For example; skin cells will migrate into a denuded patch of skin, 
creating islands of normal skin which will enlarge to cover the open 
area. Surviving normal cells in the field can repopulate by cell 
division. Repopulation heals acute effects and also decreases risk of 
late effects. 
Unfortunately, surviving tumor cells can also repopulate by cell 
division; so interruptions or extended treatment duration may 
decrease the probability of tumor control. 
Organs that are organized in parallel (lung, kidney, liver) can tolerate the 
loss of large portions of their volume, while linear organs (spinal cord) 
cannot. Respecting radiation tolerance of these latter organs is very 
important. Exceeding tolerance of (sacrificing) portions of lung, liver or 
kidney is acceptable, providing enough functional parenchyma is left to 
sustain the vital function of that organ and the patient’s quality of life. For 
example, the volume of lung that can be safely sacrificed depends on the 
pretreatment lung function.2 
A radiation oncologist aims to deliver an effective dose to the tumor, while 
delivering as low a dose as possible to the surrounding normal tissue. 
Radiation dose is a very complicated concept, as it depends not only on 
the total dose, but also fraction size, and treatment duration. For example, 
3000 cGy delivered in 5 fractions would be more potent than the same 
dose delivered in 10 fractions, and daily treatments are different than bi-
weekly treatments. Although smaller fraction size tends to decrease late 
effects, if smaller daily doses are used, a higher total dose is required to 
achieve the same level of tumor control. However, the longer regimen is 
likely to decrease both acute and late effects. 
The volume of irradiated normal tissue has a major impact on treatment 
tolerance, even though it is not recorded in the prescription or reported in 
studies. Large fields will tolerate less dose. Fortunately, control of 
microscopic disease requires less dose than control of gross tumor 
deposits. Often, smaller fields will be used at the end of treatment to 
provide adequate dose to the tumor; this is referred to as the “shrinking 
field technique” and the smaller field is called “the boost”. 
Since radiation cell kill depends on the random distribution of energy 
deposition in the cell, there is no way to guarantee the effectiveness of a 
course of radiotherapy, nor can we accurately predict toxicity expected 
from a certain dose.2 Dose response curves are asymptotic to both the 
100% and the 0% probability of a given outcome. Figure 1 shows the 
classic S-shaped dose response curve. 
 
Figure 1. Dose Response Curve. Courtesy of the University of Massachusetts 
Medical School, Department of Radiation Oncology. 
When plotting both the probability of a late effect and of tumor control on 
the same diagram, the curves are approximately parallel. The ratio 
between the 50% point on the 2 curves is called the therapeutic ratio. The 
therapeutic ratio is favorable when the complication curve (CC) is to the 
right of the tumor control curve, and unfavorable when CC is to the left 
(Figure 2). The therapeutic ratio for complication-free survival versus 
tumor control is an important part of the risk/benefit analysis. 
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Figure 2. Therapeutic Ratio Curves. Hopefully tumor control curve is to the left and 
late effect curve to the right. Courtesy of the University of Massachusetts Medical 
School, Department of Radiation Oncology. 
Surgery or pre-radiation chemotherapy may improve the risk/benefit 
calculation by reducing tumor burden; because a lower dose of radiation 
is needed to eradicate residual microscopic disease than would have been 
needed to sterilize a bulky tumor. 
Radioprotection and Radiosensitization 
When the therapeutic ratio is unfavorable, attempts to control the cancer 
involve protection of normal tissues, radiosensitization of tumor cells, or 
both. Both radioprotection and radiosensitization are attempts to improve 
the therapeutic ration, by shifting the late effect curve to the right or the 
tumor control curve to the left. 
Radioprotection: Decreasing the effective dose to normal cells, either by 
decreasing the fraction size or improving the normal tissue dose 
distribution (physical radioprotection) will improve the therapeutic ratio. 
Attempts to develop drugs to chemically protect cells have been largely 
unsuccessful (with the exception of amifostine, developed by the army for 
protection against nuclear attack, during the Cold War), and pilocarpine, a 
cholinergic agonist that protects salivary function to some extent during 
RT affecting salivary glands. 
Radiosensitization: Since oxygen is required for effective radiotherapy, 
and since tumors almost always contain hypoxic areas, improving delivery 
of oxygen to tumor cells may improve clinical outcomes. Although 
pressurized oxygen has not been demonstrated to improve the therapeutic 
ratio, randomized data suggests that raising depressed hemoglobin levels 
enhances tumor control, presumably by increasing tissue oxygen levels. 
Hyperthermia, either before or after irradiation, has been shown to 
radiosensitize tumor cells. This effect is not related to the presence of 
oxygen; in fact, cells in a hypoxic environment are more sensitive to 
hyperthermia. Delivering and maintaining heat homogenously has been 
challenging. 
Very commonly, chemotherapy is administered concomitantly with 
radiation to sensitize the malignant cells to radiation. The treatment of 
many cancers, including anal, head and neck, lung and cervix cancer has 
been transformed by the use of concomitant chemoradiotherapy. The 
effective and safe dose of both drugs and radiation, however, must be 
determined for each drug or combination regimen, since radiosensitizing 
agents make normal cells more radiosensitive too. 
Medical Imaging 
The effective delivery of radiation therapy has always required an 
anatomic target. Originally, the target was defined by physical 
examination, plain radiographs, surgical findings (and metallic clips placed 
during surgery) (Figure 3) and analysis of patterns of disease spread 
demonstrated in surgical and autopsy series. 
 
Figure 3. 3a. Surgical clips defining a tumor bed after removal of the tumor; the 
seroma adequately defines the tumor bed, and the clips add little additional 
information. 3b.Clips defining a tumor bed after removal of the tumor; here, the 
clips are very useful, since the tumor bed is difficult to see on CT. Images courtesy 
of the University of Massachusetts Medical School, Department of Radiation 
Oncology. 
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The advent of CT, MRI and PET scanning has dramatically altered the 
treatment planning process.3 Treatment planning is now done virtually, in 
the computer, using three-dimensional imaging from CT image sets 
obtained with the patient immobilized in the treatment position. MRI 
(Figure 4 a, b, c, d & e) and PET scans Figure 5 a-g) can be fused into 
these planning CT scans, enabling precise tumor delineation and close 
conformity to the shape of the tumor (3-D conformal RT) and technological 
advances in treatment delivery allow precise localization of dose in small 
volumes of the target and surrounding normal tissue, Intensity Modulated 
Radiation Therapy (IMRT). As a result of better imaging, more normal 
tissue is spared irradiation This physical radioprotection allows dose 
escalation without increasing toxicity (Figure 4 f, g & h and Movie 1). 
Figure 4. MRI impact on treatment planning: 
 
Figure 4a, b. 4a. Treatment planning CT of patient with brain metastases; no 
tumor is visible. 4b. The same planning scan slice with MRI fused and displayed: 
50% MRI, 50% CT. Notice tumor is now clearly visible just to left of ventricle. 
Images courtesy of the University of Massachusetts Medical School, Department 
of Radiation Oncology. 
 
Figure 4c- e. 4c. Treatment planning CT of patient with brain metastases; no 
tumor is visible, but there is a hint of edema in right occipital lobe (arrow). 4d. The 
same planning scan slice with MRI fused and displayed: 50% MRI, 50% CT. Notice 
tumor (red arrow) is now clearly visible in posterior portion of edema, which is much 
more visible on the MRI image. 4e. MRI fused into treatment planning CT, with 
dosimetric lines defining treatment, with 100% line (yellow) (prescription dose) 
covering target volume. Red dot is pixel receiving maximum dose. Images courtesy 
of the University of Massachusetts Medical School, Department of Radiation 
Oncology. 
 
 
Figure 4f- h. Demonstrating transverse plane isodose distributions for a range of 
clinical target volumes (CTV): 4f. 0.1 cm3; 4g. 1.1 cm3; and 4h. 12.6 cm3. Notice 
how well the smaller volumes treatments can spare overlying brain. Images 
courtesy of the University of Massachusetts Medical School, Department of 
Radiation Oncology. 
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Movie 1. Demonstrates intensity modulated radiation therapy treatment. Note the 
movement of the table and the blocks to shield organs at risk. Courtesy of the 
University of Massachusetts Medical School. Department of Radiation Oncology. 
If you have problems loading the movies, try installing the Flash plug-in found at:  
http://helpx.adobe.com/acrobat/kb/reader-acrobat-flash-player-download.html. 
Figure 5. PET impact on treatment planning: 
 
Figure 5a, b. Diagnostic tomographic PET/CT fused images. Images courtesy of 
the University of Massachusetts Medical School, Department of Radiology. 
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Figure 5c- e. 5c. CT slice through chest demonstrating a mass, possibly collapsed 
lung tissue. 5d. PET slice demonstrating FDG avidity in the mass. Note the limited 
anatomic specificity seen on PET alone. 5e. Fused PET/CT of above slices, 
demonstrating that entire mass is involved, therefore tumor, but the hilum is not. 
Images courtesy of the University of Massachusetts Medical School, Department 
of Radiation Oncology. 
 
Figure 5f- g. 5f. CT slice, same patient, cephalad to previous images. Arrow points 
at lymph nodes. 5g. PET/CT fusion demonstrates that these nodes are NOT FDG 
avid, therefore probably not involved. Images courtesy of the University of 
Massachusetts Medical School. Department of Radiation Oncology. 
Respiratory motion is taken into account with 4D treatment planning (the 
fourth dimension is time). Further precision of treatment is ensured by 
confirming that tumor is contained within the high dose volume despite 
physiologic motion, and knowing the extent of this motion allows use of 
tighter margins, sparing normal tissue.4 Four dimensional (4D) treatment 
planning may entail the use of advanced treatment techniques such as 
respiratory gating, which turns the beam on only during a specific portion 
of the respiratory cycle (Movie 2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Movie 2. Demonstrates the respiratory motion taken into account with 4D radiation 
treatment planning. Courtesy of the University of Massachusetts Medical School. 
Department of Radiation Oncology. 
If you have problems loading the movies, try installing the Flash plug-in found at:  
http://helpx.adobe.com/acrobat/kb/reader-acrobat-flash-player-download.html. 
Daily target localization on the treatment machine (Image Guided RT - 
IGRT), either by localizing implanted radio-opaque markers (fiducials) 
(Figure 6) or by imaging with an on board CT-scanner, called cone-beam 
CT (Figure 7) has greatly improved the accuracy of treatment delivery, 
because the prostate actually moves a bit in a living patient, largely as 
bowel and bladder variably fill and empty from day to day. 
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Figure 6. Lateral and AP radiographs of a male pelvis obtained with diagnostic 
energy x-rays on the treatment linear accelerator. Inert (not radioactive) medal 
wires were inserted into the prostate prior to treatment planning CT scan and 
outlined on the scan. The green boxes are from the outline on the planning CT 
scan. By shifting the patient so the wires are within the boxes, the radiation 
oncologist can assure that the planned dose distribution is being delivered to the 
prostate. Images courtesy of the University of Massachusetts Medical School, 
Department of Radiation Oncology. 
 
Figure 7. Cone beam CT of prostate showing location of prostate. Daily cone-
beam images enable the same adjustment of patient as fiducial markers to place 
dose distribution accurately as prostate shifts. The cone beam CT is fused with 
and beneath the planning CT, visible through viewing windows (slightly darker 
rectangles in each image above. Notice how close posterior edge of prostate and 
seminal vesicle volume is to rectum. Daily image guidance has dramatically 
decreased the incidence of post treatment rectal bleeding. 7a. Upper slice showing 
seminal vesicles, rectum (white arrow) and bladder (yellow arrow). Notice rectum 
has shifted on cone beam CT scan from planning scan in this slice. 7b. Lower slice 
showing prostate and rectum. Images courtesy of the University of Massachusetts 
Medical School, Department of Radiation Oncology. 
Cone beam CT has also enhanced the accuracy of treatment of lung 
tumors, permitting greater sparing of normal lung tissue, which is important 
as most lung cancer patients also have chronic obstructive pulmonary 
disease to one extent or another (Figure 8). 
 
Figure 8. CT of chest, right upper lobe lung tumor. Treatment planning CT on top 
of a cone beam CT taken just before a daily treatment at the end of a treatment 
course.The rectangular viewing window shows the cone beam CT information. 8a. 
Viewing window is on right side; tumor is seen on treatment planning CT before 
the start of treatment. 8b. Same slice as 8a. Viewing window now includes RUL 
tumor. Notice tumor is smaller and is encompased by target dose lines drawn on 
planning scan even though the lung has retracted and pulled the tumor noticeably 
medially. 8c. Viewing window splits tumor; bottom half of tumor is seen on 
treatment planning CTand top half is seen on cone beam CT, smaller and pulled 
medially. Images courtesy of the University of Massachusetts Medical School, 
Department of Radiation Oncology. 
Computer Science 
The great recent advances in radiotherapy (3D Conformal RT, Intensity 
Modulated RT- IMRT, IGRT) would not have been possible without the 
explosion in computer technology. Today, treatment planning is done 
almost entirely by computer. Computers also control the actual treatment 
delivery, including the positioning and motion of the leaves that shape and 
texture the treatment beams. Multi-leaf collimators have replaced lead 
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blocks for beam shaping, and can move during the actual treatment 
(IMRT). IMRT paints dose into the body, permitting tight control of dose 
distribution within the body by shaping dose around critical structures and 
the tumor. This technology enables even greater dose conformity and 
treatment of tiny volumes, as in Figures 4f and 4g. This precision allows 
for safe delivery of much higher doses than possible with traditional 
treatment planning and delivery techniques. 
Medical Physics 
The physics of ionizing radiation is the final body of knowledge required. 
X-rays, heavy particles (such as protons) and electrons are beams 
produced by machines; gamma rays are the product of radioactive decay. 
Remember, from Physics 101, that the density of any radiation (visible 
light, ultraviolet light, ionizing radiation, etc.) falls off with the square of the 
distance. This fundamental property is referred to as the Inverse Square 
Law. 
Diagnostic radiography typically uses low energy (kilovoltage) x-rays. 
Diagnostic energy x-rays (kilovoltage) can treat superficial tumors, but the 
deposition pattern delivers full dose to the skin, increases acute skin 
reaction and preferential absorption of these low energy beams in bone 
increases the risk of late bone damage. In addition, the dose delivered by 
these beams decreases (falls off) rapidly as depth in tissue increases. 
Today, electrons are more commonly used, because the dose delivered 
decrease rapidly with increasing depth in tissue, to the point of almost no 
dose deep in the body (Figure 9). 
Treatment of deep-seated tumors requires high-energy beams 
(megavoltage) that have greater penetrating power, so dose delivered at 
depth falls off more slowly than with kilovoltage radiation. Both the amount 
of skin sparing and the depth of penetration depend on the energy of the 
megavoltage beam. Megavoltage x-rays have this greater penetration, are 
not preferentially absorbed in bone, and do not deliver full dose to skin. 
This skin sparing effect is due to build-up of the free radicals generated as 
the beam penetrates into tissue Figure 10. 
Use of multiple megavoltage fields permits protection of overlying tissue 
as seen in Figure 11, a simple four field plan, by geographic dose 
distribution; before IMRT, this was commonly used for the treatment of 
prostate cancer. These techniques may still be seen in old patient records 
or in emerging countries, where contemporary technology is not yet 
available. When patients who have received radiation treatment in the past 
are seen, it is important to be aware of how they were treated. 
The ultimate use of many fields is arc therapy, using, in essence, up to 
360 fields, where the treatment head rotates around the patient; before 
IMRT, this was the best tissue sparing plan available (Figure 12).  
 
Figure 9. Depth dose curve for the clinically useful range of electron energies. 
Courtesy of the University of Massachusetts Medical School, Department of 
Radiation Oncology. 
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Figure 10. Depth dose curve for photons: 
 
Figure 10a. Kilovoltage versus megavoltage, notice kilovoltage delivers 100% at 
the surface (skin), while megavoltage spares skin, maximum dose is at a depth, 
referred to as Dmax. Blue arrow represents kilovoltage beam, also called 
orthovoltage. Red arrow represents 18 MV beam with about 3.5 cm skin sparing. 
Courtesy of the University of Massachusetts Medical School, Department of 
Radiation Oncology. 
 
Figure 10b. Depth dose curves for 2 megavoltage x-ray beams, 6 MV & 15 MV. 
Courtesy of the University of Massachusetts Medical School, Department of 
Radiation Oncology. 
Figure 11. Use of multiple beams to spare overlying normal tissue. Simplest 
example, four fields: Treatment fields and dose distributions for a 4 field plan, 
showing sparing of overlying tissue. With the use of four fields, AP, PA and laterals, 
100% of prescription dose can be delivered to the target volume, while the tissue 
in front and back receives 50-60%, the tissue laterally 40%and the 4 outside 
corners very little. Images courtesy of the University of Massachusetts Medical 
School, Department of Radiation Oncology. 
 
Figure 11a. Old fashioned orthogonal treatment planning images & 2D plan, based 
on wire contour. Notes blocks drawn with crayon, which were cut out of styrofoam 
and lead alloy poured to create custom blocks, to shape treatment fields to protect 
uninvolved normal tissue. Images courtesy of the University of Massachusetts 
Medical School, Department of Radiation Oncology. 
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Figure 11b. Contemporary digitally reconstructed radiographs (DRR) from 
planning CT, with prostate a seminal vesicles reconstructed from contouring on 
successive CT slices and single CT slice dose distribution demonstrating coverage 
of prostate, & anterior wall of rectum, with sparing of femurs and remainder of 
rectal circumference. Image courtesy of the University of Massachusetts Medical 
School, Department of Radiation Oncology. 
 
Figure 11c. A four field plan on patient CT slice for XRT for bone metastasis. Left 
image shows 100% line encompassing sacrum; notice uninvolved psoas muscles 
are partially in 100% volume. Right image shows 100% line encompassing femoral 
heads (which are treatment targets) with relative sparing of pelvic contents (which 
are not). Image courtesy of the University of Massachusetts Medical School, 
Department of Radiation Oncology. 
 
Figure 12. A dose distribution for a 360o arc plan. Notice the yellow 100% line 
tightly hugs the prostate, and the anterior wall of rectum is relatively spared 
because the dosimetry lines are concave behind the prostate. University of 
Massachusetts Medical School. Department of Radiation Oncology. 
Various heavy atomic particles have been used for radiation therapy as 
well; the only one in much use today is the proton. At great cost, proton 
beams provide great precision of conformal dose delivery, which is felt to 
be important in treating tumors close to critical structures such as the 
brainstem, and perhaps in children. 
Brachytherapy (the temporary or permanent implantation of tumors or 
body cavities with radioactive sources) is a method of focusing high doses 
of radiation into tumor while reducing dose to surrounding tissues (Figure 
13 and 14). Dose distribution depends on precise positioning of the 
radioactive sources and the physical characteristics of the individual 
isotope disintegration products. Dose rate depends on the initial 
radioactivity strength of the source and the half-life of the particular 
isotope. 
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Figure 13. CT slices through the uterus showing radioactive tube placement for 
treatment of endometrial cancer. a) Axial; b) Sagittal; c) Coronal; d) Dose cloud. 
Images courtesy of the University of Massachusetts Medical School, Department 
of Radiation Oncology. 
 
Figure 14. a. DRR: AP view of I131 permanent interstitial prostate implant b. Axial 
CT slice through this implant, showing seed placement. This patient also received 
external beam therapy as a portion of his treatment. So the white line is the 100% 
line from the brachytherapy. Note sparing of anterior rectal wall and careful seed 
placement away from urethra. University of Massachusetts Medical School. 
Department of Radiation Oncology. 
Stereotactic Radiosurgery (SRS) or Stereotactic Radiotherapy (SRT) 
The advent of CT and MRI based 3-dimensional treatment planning has 
made it possible to focus high doses of radiation accurately. SRS delivers 
an ablative dose of radiation in a single fraction, destroying both tumor and 
tissue. SRT utilizes the same technology, but fractionates therapy into 2-
5 treatments, thereby taking advantage of the 4 R’s of radiobiology. 
Precise target definition and patient immobilization are critical. Individually 
designed restraints are used to assure patient positioning. 
Stereotactic treatments rely on several technologies: 
 three-dimensional imaging that determines the exact coordinates 
of the target within the body  
 systems to immobilize and carefully position the patient  
 highly focused gamma-ray or x-ray beams that converge on a 
tumor or abnormality 
 image-guidance on the treatment table 
SRS is usually used for treating small lesions. Both SRS & SRT were 
originally used to treat brain lesions because the skull is easily 
immobilized. These treatments have been useful for the treatment of some 
non-cancerous conditions, including intracranial arteriovenous 
malformations (AVM's) and trigeminal neuralgia. 
More recently, stereotactic technology has been applied to treat 
extracranial lesions, such as liver and lung; this is called stereotactic body 
radiotherapy, (SBRT). Extracranial lesions are harder to immobilize, as 
organs move with respiration; 4D planning is necessary where respiratory 
motion is expected, as in lung and liver. 
SRS and SBRT have become much more common in the last few years. 
SRS replaces whole brain radiotherapy for many cases with limited (1 to 
4 lesions) brain metastases5 (Figure 5). SBRT for small lung lesions 
without apparent nodal metastases (T1N0M0) appears to have 
comparable survival to surgical removal of these tumors, with local control 
in the range of 90%. It is now being used routinely in medically inoperable 
patients or those who refuse thoracotomy6. It has been studied against 
lobectomy, with comparable results in small studies7 additional studies are 
ongoing. SBRT is also proving to be useful for treatment of liver tumors, 
whether primary or metastatic8 (Figures 15 & 16). 
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Figure 15. SBRT of a Stage I cT1N0M0 lung tumor. 15a. CT Slice showing target 
lesion (under cross hairs). 15b. Same CT slice showing arcs used to treat the 
tumor, during treatment the linear accelerator rotates around patient as beam is 
on, and dose distribution improved from traditional arcs because IMRT is used as 
well as rotation. (Blocking leaves move as well to make dose as homogenous as 
possible.) 15 c. Dose distribution around tumor. Prescription dose line (100%) is 
yellow. Outermost dose line is 50%. Images courtesy of the University of 
Massachusetts Medical School, Department of Radiation Oncology. 
Figure 16. SBRT liver: 
 
Figure 16a. MRI of liver, notice whitish metastasis with necrotic core. 15b. Same 
patient, MRI fused with planning CT, with metastasis outlined in red (slightly 
different slice) 16c. Planning CT of another patient with liver metastasis, with target 
outlined in red, and prescription dose (100%) in yellow. Notice margin between red 
and yellow lines, to allow for respiratory motion. Images courtesy of the University 
of Massachusetts Medical School, Department of Radiation Oncology. 
The biology of SRS and SBRT are not well understood yet. It is clear that 
these treatments are ablative- they are designed to entirely kill the volume 
treated, so treatment of adjacent normal tissue must be minimized, and 
the new ability to do that makes use of these treatments possible. In 
addition to direct cell kill, vascular damage and immune effects are 
believed to contribute to the efficacy of SRS and SRT.9 The biology of 
ablative therapies is an active area of research in radiobiology. 
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Goals of Radical Treatments 
Radical RT seeks to permanently control primary tumors (often, with the 
draining lymph nodes), while limiting toxicity to acceptable levels. If the 
tumor has not already spread, eradication of the primary (and regional 
nodes) will cure the patient. RT has the capacity to achieve control while 
preserving the affected organ, thereby enhancing long-term quality of life. 
Goals of Palliative Treatments 
Palliative RT seeks to relieve specific symptoms (such as pain or bleeding) 
while minimizing patient inconvenience and side effects. It is an effective 
modality for reducing or eliminating many tumor-associated symptoms 
requiring relief, and is often the most effective, least invasive and least 
expensive option. Unfortunately, it has been estimated that half of patients 
in the United States who might benefit from palliative radiation therapy 
have not been referred to a radiation oncologist. 
Treatment should relieve the targeted symptom for a significant length of 
time, often for the remainder of a patient’s life, while causing few, if any, 
side effects. The treatment should be planned to minimize patient 
imposition and cost (the latter is usually born by society through health 
insurance). Radiation oncologists must balance efficacy against cost, 
through the judicious use of fractionation and choice of technique. The use 
of prolonged is typically unwarranted, as symptom relief requires a lower 
radiation dose than is necessary for tumor eradication. However, acute 
normal tissue tolerances must be accounted for; a high daily dose to bowel 
may cause significant gastrointestinal symptoms, impacting quality of life. 
The mechanism of palliative radiation is incompletely understood; it more 
likely secondary to alteration of humoral factors (perhaps an anti-
inflammatory effect) rather than tumor shrinkage, as a patient may enjoy 
dramatic pain relief without any change in tumor volume. In most cases, 
the likelihood of response is not dependent upon tumor histology (although 
there are exceptions). On the other hand, maximal pain relief may take 6-
8 weeks for some bone metastases. This seems to be due to bone healing 
after tumor cell death. Partial or complete pain relief can be expected in at 
least 60% of patients; reduction or elimination of tumor bleeding occurs in 
90%. Certain tumors (lymphoma, for example) are so radiosensitive that 
lower doses of radiation can be utilized. 
Most commonly, radiotherapy is used for palliation of pain; the second 
most common palliative use is to relieve the symptoms of brain 
metastases, and other neurologic signs & symptoms. It is also useful for 
relief of tumor bleeding, obstruction of most hollow visci, (except the biliary 
tree), and respiratory compromise due to airway obstruction or post 
obstructive pneumonia. Disfiguring lesions of Kaposi’s sarcoma reliably 
respond to palliative RT. The efficacy of RT in palliating painful, draining 
chest wall recurrences of breast cancer was recognized more than a 
century ago. 
It is a myth that radiotherapy cannot be repeated. Many patients will 
require treatment of multiple sites over the terminal portion of their illness, 
which sometimes can last for several years, particularly for bone 
metastases, and retreatment of the same site is often possible. The brain 
will only perceive pain from 1-3 sites at a time. So it is not uncommon for 
patients to achieve good pain palliation from a course of radiotherapy and 
shortly thereafter require treatment to another site or sites, sometimes 
many times over the course of illness. 
To summarize this section: Radiotherapy is a powerful tool for palliation, 
and can improve the quality of even a short life. Retreatment is often 
possible, especially in patients for whom late effects are less of a concern. 
Conclusion 
Radiation Oncology is the medical specialty concerned with the 
prescription and delivery of RT, one of the three main modalities for 
treating cancer. Computer technology has revolutionized the field over the 
past decade, and the physicians who manage cancer patients must keep 
abreast with the changes so that their patients are not deprived of these 
advances. Although acute or long-term adverse effects may result, it is 
important to balance these risks against the risks of surgery or 
chemotherapy and for the patient and referring physicians to remember 
the goal of treatment when late effects do occur. 
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Thought Questions 
1. Why do many patients fear radiation therapy? 
Your answer: 
 
 
 
 
 
 
 
 
 
 
 
 
 
Expert Answer 
 
 
 
2. Why do most American Radiation Oncologists always prefer to 
fractionate (spread out dose over several treatments) rather than 
give a single fraction as the total treatment? 
Your answer: 
 
 
 
 
 
 
 
 
 
 
Expert Answer 
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3. When should a diagnosis of a late effect of radiation therapy be 
considered and when is such a diagnosis completely inappropriate? 
Your answer: 
 
 
 
 
 
 
 
 
 
Expert Answer 
 
 
4. Why have SRS and SRT become more commonly used in treatment? 
Your answer: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Expert Answer 
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Glossary 
Armamentarium- All of the medicines, biologics, equipment and 
techniques available to a doctor 
Benign conditions- Non-cancer diseases 
Brachytherapy- Placement of radioactive isotopes in body cavities 
(nasopharynx, gyn tract) [intracavitary brachytherapy] or tissues (prostate, 
breast) [interstitial brachytherapy] 
cGy- (centiGray)- A unit of radiation measurement: 100 cGy=1 Gy 
Conventional fractionation- A defined schedule for delivering small doses 
of the total radiotherapy dose at regular intervals 
Course of radiation- A complete treatment delivered to a single volume, 
whether in one sitting or over several months 
Dose cloud- An image of a dose distribution in the body, often shown in a 
3-dimensional image 
Fractionated radiation therapy- A course of radiation delivered in multiple 
daily or several times/day doses, called fractions 
Fraction size- Number of centiGray (cGy) delivered in a single radiation 
therapy treatment session 
Glutathione- A naturally occurring compound; cellular defense against free 
radical damage of DNA 
Half-life- The time for half of the radioactive atoms in a sample to undergo 
radioactive decay 
Hyperthermia- Heating tumor, to about 43o C for a defined time 
Potentially lethal damage- Genetically damaged cell can repair 
Radiosensitizer- An agent that increases the damage a specified dose of 
radiation does to a cell 
Teletherapy- External beam radiotherapy given from a distance 
Therapeutic ratio- The ratio between the dose providing a 50% probability 
of tumor control and the dose for a 50% probability of a given complication 
Tumorcidal- Dose that will kill tumor cells 
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Western medicine had been dominated for almost two millennia by the 
concepts of Hippocrates as codified by Galen. Disease was believed to be 
secondary to an imbalance of ‘humours’ that could be righted by purgings, 
bleedings, diaphoresis, and emesis. But discoveries in anatomy, 
physiology, microbiology, and immunology in the 18th and 19th century 
rendered the Galenic system of medicine untenable. Appearing in its place 
was the revival of folk healing arts (herbology, therapeutic baths, 
massage) as well as the appearance of new therapies (homeopathy, 
electrotherapy, osteopathy). In the last decade of the 19th century, a Dane, 
Nils Finsen, introduced a system of light therapy for which he was awarded 
a Nobel Prize. Utilizing intense, focused ultra-violet light, he was able to 
successfully treat a variety of skin disorders, such as lupus vulgaris 
(cutaneous tuberculosis) and basal cell carcinoma. After Wilhelm Röntgen 
announced his discovery of a ‘new kind of ray’ in 1895, it seemed 
appropriate to apply this ultra-short wavelength light in the treatment of 
cutaneous ailments that had responded to Finsen’s light. The results were 
gratifying and, within a decade, there were over a hundred medical 
applications for x-rays. Although mostly used for benign skin disorders, 
radiotherapy proved to be effective in palliating breast cancer recurrence, 
bone metastases, and lymphomatous masses. Biologists began studying 
the effects of radiation on normal and tumor cells over a century ago, 
establishing the field of Radiobiology, which has been used to optimize 
treatment. 
Over the ensuing decades, several important discoveries expanded 
radiotherapy’s utility. Initially, therapy was delivered in a few large 
treatments. By the 1920’s, however, it was learned that ‘fractionating’ a 
treatment over an extended course was gentler on the tissues the rays 
traversed. Higher energy tubes allowed x-rays to penetrate more deeply, 
so that subsurface tumors could be targeted. Extremely powerful 
‘megavoltage’ units began appearing in the 1930’s, culminating in the 
appearance of linear accelerators in the 1960’s. Certain tumors, such as 
lymphoma and Hodgkin disease, were no longer considered hopeless; 
diseases such as laryngeal and bladder cancers could be cured without 
mutilating surgery.  
Within a few years of Röntgen’s discovery, the Curies isolated radium 
(226Ra), a material that emitted deeply penetrating γ rays with similar 
physical and biological characteristics as x-rays. Radium’s scarcity, 
however, and the expense of refining it, delayed its broad use. The 
watershed event in the therapeutic use of radioactive materials was the 
1913 Gynecologic Congress in Halle (Germany) in 1913, in which several 
papers related the dramatic response of gynecologic tumors to implanted 
mesothorium (228Ra). Radium or mesothorium could be encapsulated in 
small capsules or needles that could be temporarily implanted into tumors 
or an involved viscous. Within a decade, major institutions had refined the 
practice of brachytherapy (treatment by implantation of radioactive 
materials) and the radium industry had lowered the cost of the product. 
Brachytherapy was soon recognized as curative treatment for oral, 
urological, and gynecologic tumors; as well as palliative for esophageal, 
breast, and rectal tumors. 
Despite the demonstrated efficacy of ionizing radiation for destroying 
cancer, the practice was at risk of disappearing in the second half of the 
20th century, for several reasons: 
1. Radiation damages normal, as well as cancerous tissue 
2. Treatment providers (physicians, nurses, and ancillary personnel) 
were at risk of developing complications (including malignancy) 
from chronic radiation exposure 
3. The appearance of more skilled surgeons, as well as more 
effective surgical techniques, that rivaled radiotherapy 
4. The introduction of chemotherapy, replacing radiotherapy as 
treatment for lymphoma and as an adjuvant to surgery. 
Perhaps the most important development to advance radiotherapy was its 
transformation into a separate specialty, radiation oncology. Until fifty 
years ago, teletherapy (radiotherapy utilizing beams from an x-ray 
generator) was the provenance of dermatologists and ‘general 
radiologists’ (whose major interest was diagnostic radiology). 
Brachytherapy was utilized primarily by surgeons, for whom it was only of 
secondary interest. Radiologists solely involved in the practice of the 
treatment of cancer established their own specialty organizations, the 
International Club of Radiotherapists (1953) and its American counterpart 
(the predecessor of ASTRO, in 1958). Training programs for radiotherapy 
specialists began appearing. Academic Radiation Oncology departments 
explored and developed safer and more effective techniques and 
treatment regimens. The ‘Patterns of Care’ studies have gathered practice 
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and outcome data from academic and private practice, leading to the 
recognition and implementation of optimal therapies. The introduction of 
low-energy radionuclides and afterloading equipment has made 
brachytherapy safer for the provider. Finally, the development of imaging 
and computer technology has resulted in more focused therapy that 
spares normal tissue to an unprecedented extent. 
Radiotherapy is used more frequently today to treat malignancy than at 
any time in its history. In certain diseases (as locally-advanced cervical 
cancer) it remains the most effective therapy. It can be used to spare the 
patient from mutilating surgery (tongue, larynx, bladder, penis), or by 
preserving tissues by limiting the extent of surgical procedures (breast, 
sarcoma, brain). It offers an effective alternative for patients unsuitable for 
curative operative procedures (lung, esophagus). It improves survival as 
an adjuvant to surgery (rectum, esophagus) and allows reduced doses of 
chemotherapy (thereby reducing toxicity) when used as an adjuvant in the 
treatment of lymphoma. And it is frequently the most effective and best 
tolerated palliative therapy for patients with incurable disease. 
Radiotherapy has entered its second century as a vital form of cancer 
treatment. 
Return to Introduction 
